Pulmatrix (NASDAQ:PULM) Stock Crosses Below 50 Day Moving Average – Should You Sell?

Posted by Tammy Falkenburg on Sep 9th, 2026

Pulmatrix, Inc. (NASDAQ:PULM – Get Free Report) shares crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $1.62 and traded as low as $1.36. Pulmatrix shares last traded at $1.3950, with a volume of 7,375 shares.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut shares of Pulmatrix from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 14th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

Check Out Our Latest Research Report on Pulmatrix

Pulmatrix Stock Up 0.4%

The firm has a market capitalization of $5.09 million, a PE ratio of -1.27 and a beta of 1.90. The company has a 50-day moving average of $1.62 and a 200 day moving average of $1.63.

Pulmatrix (NASDAQ:PULM – Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($2.00) by $1.71.

Institutional Investors Weigh In On Pulmatrix

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Dimensional Fund Advisors LP bought a new stake in Pulmatrix during the third quarter valued at approximately $52,000. DRW Securities LLC purchased a new position in Pulmatrix in the 4th quarter worth approximately $46,000. Finally, BlackRock Inc. bought a new position in shares of Pulmatrix in the 2nd quarter worth $93,000. 11.84% of the stock is owned by hedge funds and other institutional investors.

Pulmatrix Company Profile

(Get Free Report)

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).